PCN3: COMPARISON OF COSTS AND EFFECTS OF PROPHYLACTIC PAMIDRONATE FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PATIENTS WITH ADVANCED BREAST CANCER IN POLAND (COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS)

E Orlewska

doi:10.1016/s1098-3015(11)70758-6

PCN3: COMPARISON OF COSTS AND EFFECTS OF PROPHYLACTIC PAMIDRONATE FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PATIENTS WITH ADVANCED BREAST CANCER IN POLAND (COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS)

Value in Health ◽

10.1016/s1098-3015(11)70758-6 ◽

2000 ◽

Vol 3 (5) ◽

pp. 351 ◽

Cited By ~ 1

Author(s):

E Orlewska

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis ◽

Skeletal Related Events

Download Full-text

Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer

Supportive Care in Cancer ◽

10.1007/s005200050260 ◽

1999 ◽

Vol 7 (4) ◽

pp. 271-279 ◽

Cited By ~ 38

Author(s):

G. Dranitsaris ◽

Tom Hsu

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis ◽

Skeletal Related Events

Download Full-text

Abstract P4-12-08: Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis

10.1158/1538-7445.sabcs17-p4-12-08 ◽

2018 ◽

Author(s):

J Raphael ◽

J Helou ◽

DM Naimark

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis ◽

Hormone Receptor Positive

Download Full-text

PCN35 A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)

Value in Health ◽

10.1016/s1098-3015(10)67273-7 ◽

2005 ◽

Vol 8 (6) ◽

pp. A44

Author(s):

M Pangali ◽

A Christodoulopoulou ◽

A Ardavanis ◽

V Barbounis ◽

E Galani ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Line Treatment ◽

Second Line ◽

Utility Analysis ◽

Preliminary Results

Download Full-text

Palbociclib in advanced breast cancer: A cost-utility analysis

Annals of Oncology ◽

10.1093/annonc/mdx375.004 ◽

2017 ◽

Vol 28 ◽

pp. v396

Author(s):

J. Raphael ◽

J. Helou ◽

D.M. Naimark

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis

Download Full-text

PCN32 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

Value in Health ◽

10.1016/s1098-3015(10)68942-5 ◽

2007 ◽

Vol 10 (3) ◽

pp. A133

Author(s):

J Walczak ◽

D Pawlik ◽

R Wojcik ◽

M Kaczor ◽

J Lis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Neoadjuvant Therapy ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis

Download Full-text

PCN4 COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER

Value in Health ◽

10.1016/s1098-3015(10)65738-5 ◽

2004 ◽

Vol 7 (6) ◽

pp. 670

Author(s):

J Ryan ◽

M Hirsch ◽

H Knight

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Line Treatment ◽

Second Line ◽

Utility Analysis

Download Full-text

Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate

Anti-Cancer Drugs ◽

10.1097/00001813-200008000-00012 ◽

2000 ◽

Vol 11 (7) ◽

pp. 591-601 ◽

Cited By ~ 26

Author(s):

George Dranitsaris ◽

Pauline Leung ◽

Jennifer Mather ◽

Amit Oza

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitors ◽

Hormonal Therapy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Megestrol Acetate ◽

Second Line ◽

Utility Analysis

Download Full-text

PCN68 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

Value in Health ◽

10.1016/s1098-3015(10)66604-1 ◽

2008 ◽

Vol 11 (6) ◽

pp. A481

Author(s):

J Walczak ◽

E Gebus ◽

K Lasota ◽

A Semeniuk ◽

D Pawlik ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Neoadjuvant Therapy ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis ◽

Standard Regimen

Download Full-text

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis

European Journal of Cancer ◽

10.1016/j.ejca.2017.08.018 ◽

2017 ◽

Vol 85 ◽

pp. 146-154 ◽

Cited By ~ 15

Author(s):

J. Raphael ◽

J. Helou ◽

K.I. Pritchard ◽

D.M. Naimark

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis ◽

Hormone Receptor Positive

Download Full-text

Cost Utility Analysis of First-Line Hormonal Therapy in Advanced Breast Cancer

American Journal of Clinical Oncology ◽

10.1097/01.coc.0000021042.55557.2b ◽

2003 ◽

Vol 26 (3) ◽

pp. 289-296 ◽

Cited By ~ 7

Author(s):

George Dranitsaris ◽

Shailendra Verma ◽

Maureen Trudeau

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormonal Therapy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis ◽

First Line

Download Full-text